Back to News
Market Impact: 0.2
BAYER AG: AskBio's Viralgen,EpilepsyGTx Partner To Advance AAV Gene Therapy For Epilepsy
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
EpilepsyGTx entered a collaboration with Viralgen to support development and manufacturing of AAV gene therapies for drug-resistant epilepsy. The agreement is a positive operational step for EpilepsyGTx's clinical-development capabilities, though no financial terms, program milestones, or commercial impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Xencor reports phase 1 data for cancer drug XmAb819
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong
- The U.S. military and NASA have power problems. Nuclear microreactors might solve both
- Biotech stocks are surging. How investors can play the new drug innovation boom
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Family Offices: A Stack by Decision Type
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs